Green light from the World Health Organization (WHO) for the emergency use of the Chinese vaccine Sinopharm, the first to receive WHO authorization. The general manager announced it Tedros Adhanom Ghebreyesus, specifying that it is the sixth vaccine to receive validation “for safety, efficacy and quality”.
Sinopharm is a vaccine based on the inactivated Sars-CoV-2 coronavirus. Its easy-to-keep requirements make it particularly suitable for poor countries, highlights the WHO.
Covid, EMA and WHO authorization is closer for Chinese vaccines. But the published data are still few
by Elena de Stabile
The Geneva agency recommends the vaccine for adults aged 18 years and older, in a two-dose schedule with an interval of 3 to 4 weeks between each other. Vaccine efficacy for symptomatic and hospitalized disease was estimated at 79%, all age groups combined.
.